• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 3:38:03 PM ET
    $UROV
    Major Pharmaceuticals
    Health Care
    Get the next $UROV alert in real time by email
    SC 13G/A 1 d101971dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Urovant Sciences Ltd.

    (Name of Issuer)

    Common Shares, par value $0.000037453

    (Title of Class of Securities)

    G9381B 108

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G9381B 108

     

      1    

      NAMES OF REPORTING PERSONS

     

      Perceptive Advisors LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      3,116,831

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      3,116,831

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,116,831

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.8%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IA


    CUSIP No. G9381B 108

     

      1    

      NAMES OF REPORTING PERSONS

     

      Joseph Edelman

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      3,116,831

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      3,116,831

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,116,831

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.8%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN


    CUSIP No. G9381B 108

     

      1    

      NAMES OF REPORTING PERSONS

     

      Perceptive Life Sciences Master Fund, Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      3,116,831

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      3,116,831

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,116,831

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.8%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO

     


    Item 1(a).

    Name of Issuer:

    Urovant Sciences Ltd. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common Shares, par value $0.000037453 (“Common Shares”)

     

    Item 2(e).

    CUSIP Number:

    G9381B 108

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 31,659,870 outstanding Common Shares as reported in the Issuer’s Form 10-Q filed on November 2, 2021.

    The Master Fund directly holds 3,116,831 Common Shares. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Master Fund.


    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 16, 2021

     

    PERCEPTIVE ADVISORS LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title:   Managing Member

    /s/ Joseph Edelman

    JOSEPH EDELMAN
    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title:   Managing Member
    Get the next $UROV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UROV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UROV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902

      Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-blind, placebo-controlled exploratory study of URO-902, an investigational, novel, locally injected gene therapy product (plasmid human cDNA encoding maxi-K channel), in patients with overactive bladder (OAB), who were not well managed by oral therapies. "URO-902 showed a clinically meaningful and statistically significant effect on a number of relevant outcome measures in OAB including number of micturitions, urgency

      3/7/22 11:56:00 AM ET
      $MYOV
      $UROV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg

      Data from the 12-week EMPOWUR trial regarding patient perceptions of improvement of OAB symptoms show that significantly more patients treated once-daily with GEMTESA® (vibegron) experienced patient-perceived improvements due to the reduction in micturition frequency (urination), urinary urgency episodes, and urge urinary incontinence episodes vs. placebo. This analysis supports that the statistically significant reductions in clinical endpoints seen in the EMPOWUR trial are meaningful to patients. Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced today that the journal Advances in Therapy has published patient-perception data supporting clinica

      12/20/21 12:11:00 PM ET
      $MYOV
      $UROV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients

      Data from a dedicated ambulatory blood pressure study showed once-daily treatment with GEMTESA® was not associated with statistically significant or clinically meaningful effects on blood pressure or heart rate Urovant Sciences, Inc., a wholly- owned subsidiary of Sumitovant Biopharma Ltd., announced today that the journal Blood Pressure Monitoring has published the ambulatory blood pressure data on its recently-approved overactive bladder (OAB) therapy, GEMTESA® (vibegron) in the U.S. The peer-reviewed publication is currently available online and the print article is scheduled to be published in an upcoming issue of the journal. In a dedicated, double-blind, placebo-controlled ambulat

      11/8/21 8:00:00 AM ET
      $MYOV
      $UROV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $UROV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for GEMTESA

      Submission status for UROVANT SCIENCES GMBH's drug GEMTESA (ORIG-1) with active ingredient VIBEGRON has changed to 'Approval' on 12/23/2020. Application Category: NDA, Application Number: 213006, Application Classification: Type 1 - New Molecular Entity

      12/23/20 2:41:16 PM ET
      $UROV
      Major Pharmaceuticals
      Health Care
    • FDA Approval for

      Submission status for UROVANT SCIENCES GMBH's drug (ORIG-1) with active ingredient has changed to 'Approval' on 12/23/2020. Application Category: NDA, Application Number: 213006, Application Classification: Type 1 - New Molecular Entity

      12/23/20 2:41:16 PM ET
      $UROV
      Major Pharmaceuticals
      Health Care

    $UROV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Urovant Sciences Ltd.

      SC 13D/A - Urovant Sciences Ltd. (0001740547) (Subject)

      3/30/21 12:12:59 PM ET
      $UROV
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Urovant Sciences Ltd. (0001740547) (Subject)

      2/16/21 3:38:03 PM ET
      $UROV
      Major Pharmaceuticals
      Health Care

    $UROV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: E. Bryan Smith disposed to the issuer $0 worth of Common Shares (124,447 units at $0.00), decreasing direct ownership by 100% to 0 units

      4 - Urovant Sciences Ltd. (0001740547) (Issuer)

      3/31/21 12:30:26 PM ET
      $UROV
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: M. James Hindman disposed to the issuer $0 worth of Common Shares (9,000 units at $0.00), decreasing direct ownership by 100% to 0 units

      4 - Urovant Sciences Ltd. (0001740547) (Issuer)

      3/31/21 12:30:36 PM ET
      $UROV
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Cornelia Haag-Molkenteller disposed to the issuer $0 worth of Common Shares (141,348 units at $0.00), decreasing direct ownership by 100% to 0 units

      4 - Urovant Sciences Ltd. (0001740547) (Issuer)

      3/31/21 12:30:43 PM ET
      $UROV
      Major Pharmaceuticals
      Health Care

    $UROV
    SEC Filings

    See more
    • SEC Form 15-12B filed by Urovant Sciences Ltd.

      15-12B - Urovant Sciences Ltd. (0001740547) (Filer)

      4/8/21 4:08:51 PM ET
      $UROV
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Urovant Sciences Ltd.

      EFFECT - Urovant Sciences Ltd. (0001740547) (Filer)

      4/1/21 12:15:11 AM ET
      $UROV
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13E3/A filed by Urovant Sciences Ltd.

      SC 13E3/A - Urovant Sciences Ltd. (0001740547) (Subject)

      3/29/21 5:20:26 PM ET
      $UROV
      Major Pharmaceuticals
      Health Care